C
CellPhire
Focused on developing platelet-based products to save lives
About CellPhire
Cellphire, Inc. is a biotechnology company specializing in cell stabilization technology, with a primary focus on blood platelets. The company has developed a proprietary method for the long-term stabilization of platelets in a dry state, which addresses the fragility of the national platelet supply. This technology is particularly crucial during natural or man-made disasters that could disrupt the constant supply needed for treating bleeding disorders. Cellphire operates in the healthcare and biotechnology market, serving clients such as hospitals, blood banks, and military medical units. The business model is based on the development and commercialization of its proprietary stabilization technology, which is currently in Phase 1 clinical trials. Revenue is generated through product sales, research grants, and partnerships with government agencies like the Biomedical Advanced Research Defense Authority (BARDA).
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- Rockville, United States
- Employees
- 48
- Open positions
- 2
- Dealroom signal
- 34.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBT✓Debt | Sep 2023 | $2M | — | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Apr 2021 | $15M | $60M | Simcah Management | — |
Growth signals
Latest recorded traffic for CellPhire is 3.8K monthly website visits, up 123.5% over the last three months. CellPhire's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- SMSimcah Management
Series B and later1 investor entered at this stage
Maryland Venture Fund
Other known investors6 additional known investors
11-11 Ventures
Circadian Ventures
Maryland Industrial Partnerships
Mike Dowdle
Small Business Innovation Research
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CellPhire on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CellPhire’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.